1. Home
  2. UCAR vs NSRX Comparison

UCAR vs NSRX Comparison

Compare UCAR & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$1.35

Market Cap

35.5M

ML Signal

HOLD

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$3.01

Market Cap

32.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCAR
NSRX
Founded
2013
2019
Country
China
Israel
Employees
N/A
7
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.5M
32.2M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
UCAR
NSRX
Price
$1.35
$3.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$50.00
$19.67
AVG Volume (30 Days)
480.7K
53.9K
Earning Date
05-15-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$1.98
52 Week High
$4.98
$9.99

Technical Indicators

Market Signals
Indicator
UCAR
NSRX
Relative Strength Index (RSI) 46.86 48.07
Support Level $1.14 $2.04
Resistance Level $1.68 $3.48
Average True Range (ATR) 0.11 0.28
MACD -0.01 0.01
Stochastic Oscillator 22.77 32.03

Price Performance

Historical Comparison
UCAR
NSRX

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: